I-SPY2 research initiative employs new exciting model to test drugs against breast cancer -
In a new paradigm of research on breast cancer, doctors promising new drug for more rapid monitoring study, while immediately giving up drugs and combinations of drugs that do not work.
Loyola medical oncologist Kathy Albain S., MD, FACP, FASCO is a co-author of two of these studies, published in the July 7, 2016 New England Journal of Medicine . Studies have shown that patients with specific subtypes of breast cancer, drug neratinib and veliparib the combination of drug plus carboplatin were more effective in eradicating tumors prior to surgery as the standard chemotherapy alone.
The studies are part of a nationwide research initiative called I-SPY2. Dr. Albain is the principal investigator at Loyola, one of only two academic medical centers in Illinois participating in I-SPY2.
"I-SPY2 employs an exciting new model for testing drugs," said Dr. Albain. "The tests are not run this way before in breast cancer Now we can determine much more earlier that the drugs are active, while minimizing the exposure of patients to drugs that do not work - .. as the trial progresses day by day "
Dr. Albain, professor, department of medicine, division of hematology / oncology, Loyola University Chicago Stritch of School of medicine, is also a member of the National I-SPY2 New agents and wire Committee "chaperone" of another study I-SPY2 for drug trebananib experimental.
I-SPY2 researchers use profiles of breast cancer cell gene biomarkers to determine which experimental study drug is most suited to the profile of the tumor of a given patient.
"patient treatment is targeted, real-time, the biology of the tumor," said Dr. Albain. "I-SPY2 allows us to bring exciting new agents in the curative setting faster than the standard method of the first test extensively in large multi-year trials."
The I-SPY2 studies were conducted in patients before they underwent surgery. These studies allow drugs to be tested in small trials, with faster results.
The researchers examined whether experimental treatments have resulted in the complete eradication of tumors before surgery. eradication of the tumor does not necessarily mean a patient is cured and must still undergo surgery. But women who experience eradicating tumor before surgery were less likely to relapse or die of breast cancer.
In one SPY2 I-studies published recently, the researchers examined the drug neratinib, who was very active in patients with a type of breast cancer known as HER2-positive name, negative hormone receptors. Fifty-six percent of patients who were treated with neratinib and the eradication of standard treatment known tumor before surgery, compared to 33 percent of patients who received standard therapy alone
. The second trial involved patients who had a type of breast cancer called triple negative cancer. Fifty-one percent of women who received veliparib and carboplatin with standard therapy experienced eradication of the tumor before surgery, compared to 26 percent of women who received standard treatment alone.
Based on these results, experimental drugs are being accelerated large-scale phase 3
in an article accompanying perspective, researchers at the Dana-Institut Farber Cancer and the Harvard school of public health, who are not involved in the trial, wrote that I- SPY2 is "an important addition to the inventory of test designs." the authors perspective, David Harrington, PhD, and Giovanni Parmigiani, PhD, concluded: "We applaud the use of I-SPY2 described here and urge continued innovation in trial design, especially in the two phases 1 and later 3 previous settings. "
EmoticonEmoticon